Allogene Therapeutics (ALLO) Other Operating Expenses (2019 - 2025)

Allogene Therapeutics has disclosed Other Operating Expenses across 4 years of filings, most recently posting $2.4 million for Q2 2025.

• Other Operating Expenses for Q2 2025 came in at $2.4 million, down 52.25% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.4 million (down 84.84% YoY), and the FY2025 annual result was $2.4 million, down 84.84% from the prior year.
• Other Operating Expenses came in at $2.4 million for Q2 2025 at Allogene Therapeutics, down from $10.7 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $13.2 million in Q4 2023 to a low of $2.4 million in Q2 2025.
• The 3-year median for Other Operating Expenses is $7.9 million (2024), against an average of $7.8 million.
• Peak annual rise in Other Operating Expenses reached 52.25% in 2025, while the deepest fall reached 52.25% in 2025.
• Allogene Therapeutics' Other Operating Expenses stood at $13.2 million in 2023, then slipped by 19.0% to $10.7 million in 2024, then plunged by 77.8% to $2.4 million in 2025.
• The last three Other Operating Expenses figures came in at $2.4 million (Q2 2025), $10.7 million (Q3 2024), and $5.0 million (Q2 2024), per Business Quant data.